Literature DB >> 26610927

Application of albumin-based nanoparticles in the management of cancer.

Xinzhe Yu1, Chen Jin2.   

Abstract

Over the past three decades, tremendous progress has been made in cancer prevention and treatment. Despite these advances, a substantial number of cancer cases experience early recurrence and metastases. Thus, the better management of cancer, especially developing more effective drugs for combating cancer cells, is an arduous task. Albumin-based nanoparticles are emerging as a promising approach to replace the traditional way of carrying therapeutic drugs to a tumor site. In this review, we describe the basic knowledge on albumin-based nanoparticles, recent progress of using albumin-based nanoparticles in the diagnosis and treatment of cancer, and the application of nanoparticle albumin bound (Nab) paclitaxel for the treatment of lung, breast and pancreatic cancer. Last but not least, we try to discuss future goals and perspectives in the field of drug delivery research, thereby facilitating the antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26610927     DOI: 10.1007/s10856-015-5618-9

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  99 in total

1.  Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.

Authors:  Natsuko Kawada; Hiroyuki Uehara; Kazuhiro Katayama; Satoaki Nakamura; Hidenori Takahashi; Hiroaki Ohigashi; Osamu Ishikawa; Shigenori Nagata; Yasuhiko Tomita
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-11       Impact factor: 7.027

Review 2.  Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.

Authors:  Felix Kratz; André Warnecke
Journal:  J Control Release       Date:  2012-06-13       Impact factor: 9.776

3.  On-site preparation of technetium-99m labeled human serum albumin for clinical application.

Authors:  Yuh-Feng Wang; Mei-Hua Chuang; Jainn-Shiun Chiu; Thau-Ming Cham; Mei-Ing Chung
Journal:  Tohoku J Exp Med       Date:  2007-04       Impact factor: 1.848

4.  Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.

Authors:  Claudia Fiorini; Marco Cordani; Chiara Padroni; Giovanni Blandino; Silvia Di Agostino; Massimo Donadelli
Journal:  Biochim Biophys Acta       Date:  2014-10-13

5.  NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA.

Authors:  Shan Jiang; Yong Zhang; Kian Meng Lim; Eugene K W Sim; Lei Ye
Journal:  Nanotechnology       Date:  2009-03-24       Impact factor: 3.874

6.  Engineering of near IR fluorescent albumin nanoparticles for in vivo detection of colon cancer.

Authors:  Sarit Cohen; Shlomo Margel
Journal:  J Nanobiotechnology       Date:  2012-08-14       Impact factor: 10.435

7.  Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis.

Authors:  Safaa Sebak; Maryam Mirzaei; Meenakshi Malhotra; Arun Kulamarva; Satya Prakash
Journal:  Int J Nanomedicine       Date:  2010-09-20

8.  Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT).

Authors:  Atul Dhabuwala; Prue Lamerton; Richard S Stubbs
Journal:  BMC Nucl Med       Date:  2005-12-23

9.  Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells.

Authors:  Chen Xia; Fugui Ye; Xin Hu; Zhengdong Li; Beiqi Jiang; Yun Fu; Xiaolin Cheng; Zhiming Shao; Zhigang Zhuang
Journal:  Oncol Lett       Date:  2014-08-14       Impact factor: 2.967

Review 10.  Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field.

Authors:  Xiaomin Yi; Fuli Wang; Weijun Qin; Xiaojian Yang; Jianlin Yuan
Journal:  Int J Nanomedicine       Date:  2014-03-05
View more
  4 in total

1.  High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.

Authors:  Federico Coccolini; Fabio Acocella; Lavinia Morosi; Stefano Brizzola; Matteo Ghiringhelli; Marco Ceresoli; Enrico Davoli; Luca Ansaloni; Maurizio D'Incalci; Massimo Zucchetti
Journal:  Pharm Res       Date:  2017-02-28       Impact factor: 4.200

2.  Development of doxorubicin loading platform based albumin-sporopollenin as drug carrier.

Authors:  Esra Maltas; Ilkay Hilal Gubbuk; Salih Yildiz
Journal:  Biochem Biophys Rep       Date:  2016-06-16

3.  Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells.

Authors:  Ana Santos-Rebelo; Pradeep Kumar; Viness Pillay; Yahya E Choonara; Carla Eleutério; Mariana Figueira; Ana S Viana; Lia Ascensão; Jesús Molpeceres; Patrícia Rijo; Isabel Correia; Joana Amaral; Susana Solá; Cecília M P Rodrigues; Maria Manuela Gaspar; Catarina Pinto Reis
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

4.  Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases.

Authors:  Xinzhe Yu; Wenwen Zhu; Yang Di; Jichun Gu; Zhongyi Guo; Hengchao Li; Deliang Fu; Chen Jin
Journal:  Int J Nanomedicine       Date:  2017-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.